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Abstract 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly heritable childhood behavioral 
disorder affecting 5% of children and 2.5% of adults. Common genetic variants contribute 
substantially to ADHD susceptibility, but no variants have been robustly associated with ADHD. 
We report a genome-wide association meta-analysis of 20,183 ADHD diagnosed cases and 
35,191 controls that identifies variants surpassing genome-wide significance in 12 independent 
loci, revealing new and important information on the underlying biology of ADHD. Associations 
are enriched in evolutionarily constrained genomic regions, loss-of-function intolerant genes and 
around brain-expressed regulatory marks. Analyses of three replication studies; a cohort of 
diagnosed ADHD, a self-reported ADHD sample and a meta-analysis of quantitative measures of 
ADHD symptoms in the population, support these findings while highlighting study-spcific 
differences on genetic overlap with educational attainment. Strong concordance with GWAS of 
quantitative population measures of ADHD symptoms supports that clinical diagnosis of ADHD 
is an extreme expression of continuous heritable traits. 
 
Introduction 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental psychiatric disorder, 
that affects around 5% of children and adolescents and 2.5% of adults worldwide1. ADHD is 
often persistent and markedly impairing with increased risk of harmful outcomes such as 
injuries2, traffic accidents3, increased health care utilization4,5, substance abuse6, criminality7, 
unemployment8, divorce4, suicide9, AIDS risk behaviors8, and premature mortality10. 
Epidemiologic and clinical studies implicate genetic and environmental risk factors that affect 
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the structure and functional capacity of brain networks involved in behavior and cognition1, in 
the etiology of ADHD. 
 
Consensus estimates from over 30 twin studies indicate that the heritability of ADHD is 70-80% 
throughout the lifespan11,12 and that environmental risks are those not shared by siblings13.  Twin 
studies also suggest that diagnosed ADHD represents the extreme tail of one or more heritable 
quantitative traits14. Additionally, family and twin studies report genetic overlap between ADHD 
and other conditions including antisocial personality disorder/behaviours15, 
cognitive impairment16, autism spectrum disorder17,18, schizophrenia19, bipolar disorder20, and 
major depressive disorder21.  
 
Thus far genome-wide association studies (GWASs) to identify common DNA variants that 
increase the risk of ADHD have not been successful22. Nevertheless, genome-wide SNP 
heritability estimates range from 0.10 – 0.2823,24 supporting the notion that common variants 
comprise a significant fraction of the risk underlying ADHD25 and that with increasing sample 
size, and thus increasing statistical power, genome-wide significant loci will emerge.  
 
Previous studies have demonstrated that the common variant risk, also referred to as the single 
nucleotide polymorphism (SNP) heritability, of ADHD is also associated with depression25, 
conduct problems26, schizophrenia27, continuous measures of ADHD symptoms28,29 and other 
neurodevelopmental traits29 in the population. Genetic studies of quantitative ADHD symptom 
scores in children further support the hypothesis that ADHD is the extreme of a quantitative 
trait30. 
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Here we present a genome-wide meta-analysis identifying the first genome-wide significant loci 
for ADHD using a combined sample of 55,374 individuals from an international collaboration. 
We also strengthen the case that the clinical diagnosis of ADHD is the extreme expression of one 
or more heritable quantitative traits, at least as it pertains to common variant genetic risk, by 
integrating our results with previous GWAS of ADHD-related behavior in the general 
population. 
 
Results 
Genome-wide significantly associated ADHD risk loci 
Genotype array data for 20,183 ADHD cases and 35,191 controls were collected from 12 cohorts 
(Supplementary Table 1). These samples included a population-based cohort of 14,584 cases and 
22,492 controls from Denmark collected by the Lundbeck Foundation Initiative for Integrative 
Psychiatric Research (iPSYCH; Supplementary Figure 1), and 11 European, North American and 
Chinese cohorts aggregated by the Psychiatric Genomics Consortium (PGC). ADHD cases in 
iPSYCH were identified from the national Psychiatric Central Research Register psychiatric and 
diagnosed by psychiatrists at a psychiatric hospital according to ICD10 (F90.0), and genotyped 
using Illumina PsychChip. Designs for the PGC cohorts have been described 
previously24,25,31,32,22 (see Supplementary Information for detailed cohort descriptions).  
 
Prior to analysis, stringent quality control procedures were performed on the genotyped markers 
and individuals in each cohort using a standardized pipeline33 (Online Methods). Related 
individuals were removed, and genetic outliers within each cohort were excluded based on 
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principal component analysis. Non-genotyped markers were imputed using the 1000 Genomes 
Project Phase 3 reference panel34 (Online Methods).  
 
GWAS was conducted in each cohort using logistic regression with the imputed additive 
genotype dosages. Principal components were included as covariates to correct for population 
stratification35 (Supplementary Information), and variants with imputation INFO score < 0.8 or 
minor allele frequency (MAF) < 0.01 were excluded. The GWAS were then meta-analyzed using 
an inverse-variance weighted fixed effects model36. The included single Chinese cohort had 
insufficient sample size for well-powered trans-ethnic modelling (Supplementary Figure 2). 
Association results were considered only for variants with an effective sample size greater than 
70% of the full meta-analysis, leaving 8,047,421 variants in the final meta-analysis. A meta-
analysis restricted to European-ancestry individuals (19,099 cases, 34,194 controls) was also 
performed to facilitate secondary analyses (Supplementary Information).  
 
In total, 304 genetic variants in 12 loci surpassed the threshold for genome-wide significance 
(P<5´10-8; Figure 1, Table 1, Supplementary Figure 3.A2 – 3.N2). Results for the European 
ancestry meta-analysis were substantively similar (Supplementary Figure 4). No marker 
demonstrated significant heterogeneity between studies (Supplementary Figure 5 and 6) and no 
heterogeneity was observed between the Chinese and European ancestry cohorts (Supplementary 
Figure 2). Conditional analysis within each locus did not identify any independent secondary 
signals meeting genome-wide significance (Online Methods, Supplementary Table 2).   
 
Homogeneity of effects between cohorts 
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No genome-wide significant heterogeneity was observed in the ADHD GWAS meta-analysis 
(Supplementary Information). Genetic correlation analysis (Online Methods) provided further 
evidence that effects were consistent across cohort study designs. The estimated genetic 
correlation between the European ancestry PGC samples and the iPSYCH sample from LD score 
regression37 was not significantly less than one (rg = 1.17, SE = 0.20). The correlation between 
European ancestry PGC case/control and trio cohorts estimated with bivariate GREML was 
similarly close to one (rg = 1.02, SE = 0.32; Supplementary Table 3).  
 
Polygenic risk scores (PRS)38 were also consistent across target samples. PRS computed in each 
PGC study using iPSYCH as the training sample were consistently higher in ADHD cases as 
compared to controls or pseudo-controls (Supplementary Figure 7). Increasing deciles of PRS in 
the PGC were associated with higher odds ratio (OR) for ADHD (Figure 2). A similar pattern 
was seen in five-fold cross validation in the iPSYCH cohort, with PRS for each subset computed 
from the other four iPSYCH subsets and the PGC samples used as training samples (Online 
Methods; Figure 2). Across iPSYCH subsets, the mean of the maximum variance explained by 
the estimated PRS (Nagelkerke’s R2) was 5.5% (SE = 0.0012) (Supplementary Figure 8). The 
difference in standardized PRS between cases and controls was stable across iPSYCH subsets 
(OR = 1.56, 95% confidence interval [CI]: 1.53 – 1.60; Supplementary Figure 9) and across 
waves and PGC cohorts (Supplementary Figure 10). These results further support the highly 
polygenic architecture of ADHD and demonstrate that ADHD risk is significantly associated 
with PRS in a dose-dependent manner.  
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To assess the proportion of phenotypic variance explained by common variants we applied LD 
score regression37 to results from the European ancestry meta-analysis (Online Methods). 
Assuming a population prevalence of 5% for ADHD39, we estimate that the liability-scale SNP 
heritability h2snp = 0.216 (SE = 0.014, P = 8.18´10-54; Supplementary Table 4). These estimated 
polygenic effects account for 88% (SE = 0.0335) of observed genome-wide inflation of the test 
statistics in the meta-analysis (! = 1.200; see Supplementary Figure 11 for quantile-quantile 
plots); the remaining inflation, which may reflect confounding factors such as cryptic relatedness 
and population stratification, is significant but modest (intercept=1.0362, SE = 0.0099, P=2.27 ´ 
10-4).   
 
To further characterize the patterns of heritability from the genome-wide association data, we 
partitioned SNP heritability by functional annotations as described in Finucane et al.40 using 
partitioned LD Score regression (Online Methods). The analysis revealed significant enrichment 
in the heritability from SNPs located in conserved regions (P = 8.49 ´ 10-10; Supplementary 
Figure 12), supporting their biological importance. Enrichment of the SNP heritabilty in cell-
type-specific regulatory elements was evaluated using the cell-type-specific group annotations 
described in Finucane et al40. We observed a significant enrichment of the average per SNP 
heritability for variants located in central nervous system specific regulatory elements 
(enrichment = 2.44, SE = 0.35, P = 5.81 ´ 10-5; Supplementary Figures 13 and 14).  
 
Genetic correlation with other traits 
Pairwise genetic correlation with ADHD was estimated for 219 phenotypes using LD score 
regression41,42 (Online Methods, Supplementary Data 1). Fourty-three phenotypes demonstrated 
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significant genetic overlap with ADHD (P < 2.28 ´ 10-4), including major depressive disorder43, 
anorexia nervosa44, educational outcomes45-49, obesity-related phenotypes50-55, smoking56-58, 
reproductive success59, insomnia60, and mortality61 (Figure 3; Supplementary Table 5). In most 
domains the genetic correlation is supported by GWAS of multiple related phenotypes. For the 
positive genetic correlation with major depressive disorder (rg = 0.42, P = 7.38 ´ 10-38), we also 
observe a positive correlation with depressive symptoms (rg = 0.45, P = 7.00 ´ 10-19), neuroticism 
(rg = 0.26, P= 1.02 ´ 10-8) and a negative correlation with subjective well-being (rg = -0.28, P = 
3.73 ´ 10-9). The positive genetic correlations with ever smoked (rg = 0.48, P= 4.33 ´ 10-16) and 
with number of cigarettes smoked (rg = 0.45, P = 1.07 ´ 10-5) are reinforced by significant 
positive correlation with lung cancer (rg = 0.39, P= 6.35 ´ 10-10). Similarly, genetic correlations 
related to obesity include significant relationships with body mass index (BMI; rg = 0.26, P = 
1.68 ´ 10-15), waist-to-hip ratio (rg = 0.30, P= 1.16 ´ 10-17), childhood obesity (rg = 0.22, P = 3.29 
´ 10-6), HDL cholesterol (rg = -0.22, P = 2.44 ´ 10-7), and Type 2 Diabetes (rg = 0.18, P = 7.80 ´ 
10-5). Additionally the negative correlation with years of schooling (rg = -0.53, P = 6.02 ´ 10-80) 
is supported by a negative genetic correlation with human intelligence (rg = -0.41, P = 7.03 ´ 10-
26). Finally the genetic correlation with reproduction include a negative correlation with age of 
first birth (rg = -0.612, P = 3.70 ´ 10-61) and a positive correlation with number of children ever 
born (rg = 0.42, P = 8.51 ´ 10-17). 
 
Biological annotation of significant loci 
For the 12 genome-wide significant loci, Bayesian credible sets were defined to identify the set 
of variants at each locus most likely to include a variant with causal effect (Online Methods, 
Supplementary Data 2; Supplementary Table 6). Biological annotations of the variants in the 
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credible set were then considered to identify functional or regulatory variants, common 
chromatin marks, and variants associated with gene expression (eQTLs) or in regions with gene 
interactions observed in Hi-C data (Online Methods, Supplementary Data 3). Broadly, the 
significant loci do not coincide with candidate genes proposed to play a role in ADHD62. 
 
Here we highlight genes that are identified in the regions of association (see also Supplementary 
Table 7). The loci on chromosomes 2, 7, and 10 each have credible sets localized to a single gene 
with limited additional annotations. In the chromosome 7 locus, FOXP2 encodes a 
forkhead/winged-helix transcription factor and is known to play an important role in synapse 
formation and neural mechanisms mediating the development of speech and learning63-65. 
Comorbidity of ADHD with specific developmental disorders of language and learning is 
common (7 – 11%)66,67, and poor language skills have been associated with higher 
inattention/hyperactivity symptoms in primary school68. On chromosome 10, the ADHD 
association is intronic, located in SORCS3, which encodes a brain-expressed transmembrane 
receptor that is important for neuronal development and plasticity69 and has previously been 
associated with depression43,70. 
 
Genome-wide significant loci on chromosomes 12 and 15 have more biological annotations 
supporting the co-localized genes. The credible set on chromosome 12 spans DUSP6, and 
includes an annotated missense variant in the first exon and an insertion near the transcription 
start site, though neither is the lead variant in the locus (Supplementary Data 4).  DUSP6 encodes 
a dual specificity phosphatase71, and may play a role in regulating neurotransmitter homeostasis 
by affecting dopamine levels in the synapses72,73. Regulation of dopamine levels is likely to be 
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relevant to ADHD since widely used ADHD medications have dopaminergic targets74,75 that 
increase the availability of synaptic dopamine. The chromosome 15 locus is located in SEMA6D, 
and the majority of variants in the credible set are strongly associated with expression of 
SEMA6D in fibroblasts76. SEMA6D is active in the brain during embryonic development, and 
may play a role in neuronal wiring77. Furthermore, variants in SEMA6D have previously been 
associated with eduational attainment78.  
 
Credible set annotations at the remaining loci are more diverse (Supplementary Data 3). The 
most strongly associated locus on chromosome 1 (index variant rs112984125) covers a gene-rich 
250kb region of strong LD.  The index variant is intronic to ST3GAL3, and most SNPs in the 
credible set are strongly associated with expression of ST3GAL3 in whole blood79 
(Supplementary Data 3). Missense mutations in ST3GAL3 have been shown to cause autosomal 
recessive intellectual disability80. Hi-C and eQTL annotations suggest multiple alternative genes 
however, including PTPRF (Supplementary Data 4). The locus also includes an intergenic 
variant, rs11210892, that has previously been associated with schizophrenia33.  
 
On chromosome 5, the credible set includes links to LINC00461 and TMEM161B 
(Supplementary Data 3). The function of LINC00461 is unclear, but the RNA has highly 
localized expression in the brain81 and the genome-wide significant locus overlaps with variants 
in LINC00461 associated with educational attainment78.  Alternatively, a genome-wide 
significant SNP in this locus (rs304132) is located in MEF2C-AS1, of strong interest given 
previous associations between MEF2C and severe intellectual disability,82-84 cerebral 
malformation83, depression70, schizophrenia33 and Alzheimer’s disease85, but the corresponding 
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variant is not supported by the credible set analysis. Credible set annotations for other significant 
loci are similarly cryptic.  
 
Analysis of gene sets  
Competitive gene based tests were performed for FOXP2 target genes, highly constrained genes, 
and for all Gene Ontology terms86 from  MsigDB 6.087 using MAGMA88 (Online Methods). 
Association results for individual genes are consistent with the genome-wide significant loci for 
the GWAS (Supplementary Table 8), however four new genes passed the threshold for exome-
wide significant association (Supplementary Figure 15.A-D). Three independent sets of FOXP2 
downstream target genes89,90 were tested (Online Methods), none of which demonstrated 
significant association to ADHD (Supplementary Table 9). The lack of association may be 
caused by unknown functions of FOXP2 driving ADHD risk, insufficient power to detect 
relevant downstream genes, or because only a small subset of biological functions regulated by 
FOXP2 are relevant to ADHD pathogenesis. 
 
Consistent with the partitioning of heritability, a set of 2,932 genes that are highly constrained 
and show high intolerance to loss of function91 showed significant association with ADHD (" = 
0.062, P = 2.6 ´ 10-4; Supplementary Table 10).  We also find little evidence for effects in 
previously proposed candidate genes for ADHD62; of the nine proposed genes only SLC9A9 
showed weak association with ADHD (P = 3.4 ´ 10-4; Supplementary Table 11). None of the 
Gene Ontology gene sets were significant after correcting for multiple testing, although the most 
associated included interesting nominally significant pathways such as “dopamine receptor 
binding” (P = 0.0010) and “Excitatory Synapse” (P = 0.0088; Supplementary Data 5). 
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Replication of GWAS loci 
 
For replication we evaluated the comparison of the GWAS meta-analysis of ADHD with three 
other independent ADHD-related GWASs: replication of top loci in an Icelandic cohort with 
ADHD status derived from medical records of ICD codes and medication history by deCODE 
(5,085 cases, 131,122 controls), a GWAS of self-reported ADHD status among 23andMe 
research participants (5,857 cases, 70,393 controls) and a meta-analysis of GWAS of childhood 
rating scales of ADHD symptoms performed by the EAGLE consortium (17,666 children < 13 
years of age)30 and QIMR92 (2,798 adolescents), referred to as EAGLE/QIMR throughout the 
text. Although the phenotyping and cohort ascertainment of the 23andMe and EAGLE/QIMR 
studies differ from the PGC and iPSYCH ADHD meta-analysis (Supplemenatry Information), 
they have clear relevance to understanding how the ADHD GWAS results generalize to closely 
related phenotypes. 
 
Top loci from the ADHD GWAS showed moderate concordance across the three replication 
studies. Sign concordance between each of the three replication cohorts and the ADHD GWAS 
was significantly greater than would be expected by chance (range 72–82% concordant; P < 
0.0167 = 0.05/3 replication cohorts; Supplementary Table 12) for nominally associated loci from 
the ADHD GWAS (P < 1 ´ 10-6), with the highest concordance observed in EAGLE/QIMR. The 
deCODE and 23andMe results also permit direct comparisons of the magnitude of effect sizes 
for the top loci in the ADHD loci (Supplementary Table 13). Regressing effect size estimates 
from each replication cohort on estimates from the ADHD GWAS adjusted for winner’s curse 
yields significantly positive slopes (deCODE slope = 0.664, P = 1.2 ´ 10-4; 23andMe slope = 
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0.417, P = 1.11 ´ 10-3), although these slopes are less than one, suggesting imperfect replication. 
Among the genome-wide significant loci, rs9677504 (SPAG16 locus) in deCODE and 
rs112984125 (ST3GAL3/PTPRF locus) and rs212178 (LINC01572 locus) in 23andMe are 
noteable outlers with weak replication results (Online Methods, Supplementary Figure 16-17).  
 
The genome-wide data available from 23andMe and EAGLE/QIMR showed similar trends for 
replication. The genetic correlation between EAGLE/QIMR and the ADHD GWAS was 
extremely strong (rg = 0.970, SE = 0.207, P = 2.66 ´ 10-6) and not significantly different from 
one (one-sided P = 0.442). Genetic correlation with 23andMe was weaker but still strongly 
positive (rg = 0.653, SE = 0.114, P = 1.11 ´ 10-8), although also significantly less than 1 (one-
sided P= 1.17 ´ 10-3). To explore this lower correlation we evaluated the genetic correlation 
between 23andMe and traits from LD Hub (see URLs)42 to potentially identify differences in 
the profile of genetic correlation compared to the ADHD GWAS (Online Methods). This 
comparison identified striking differences (Supplementary Table 14), most notably that the 
23andMe GWAS show little to no genetic correlation with college completion (rg = 0.056, 
compared to rg = -0.54 for the primary ADHD GWAS; approximate P = 1.1 ´ 10-9 for 
difference) and other education-related phenotypes. Genetic correlations with obesity-related 
phenotypes were similarly smaller for the 23andMe cohort. The one domain where 23andMe 
exhibited a trend toward stronger genetic correlations were schizophrenia (rg = 0.27, vs. rg = 0.12 
in ADHD, P = 0.053) and bipolar disorder (rg = 0.029, vs. rg = 0.095 in ADHD, P = 0.09), 
though these trends are not significant with the approximated test of the difference in genetic 
correlation. 
 
 17 
Finally, we meta-analyzed the ADHD GWAS with each replication cohort. For EAGLE/QIMR, 
we developed a novel model to meta-analyze the GWAS of the continuous measure of ADHD 
with the clinical diagnosis in the ADHD GWAS. In brief, we perform a Z-score based meta-
analysis using a weighting scheme derived from the SNP heritability and effective sample size 
for each phenotype that fully accounts for the differences in measurement scale (detailed 
description in Supplementary Information, and Supplementary Figures 24-26). This calibration 
based on the genome-wide estimate of heritability prevents joint meta-analysis of all replication 
cohorts since genome-wide data is not available for the deCODE study. 
 
Meta-analyses of the ADHD GWAS with each replication study identified 10 genome-wide 
significant loci (P < 5 ´ 10-8, without multiple testing correction) in meta-analysis with deCODE, 
10 significant loci with 23andMe, and 15 significant loci with EAGLE/QIMR (Supplementary 
Data 6, Supplementary Figures 18 and 19). Of the 12 significant loci from the primary ADHD 
GWAS, four were significant in all three of these replication meta-analyses: index variants 
rs11420276 (ST3GAL3/PTPRF), rs5886709 (FOXP2), rs11591402 (SORCS3), and rs1427829 
(intergenic). The remaining loci were all significant in at least one of the replication meta-
analyses. In addition, ten novel loci reached genome-wide significance in the replication meta-
analyses, of which three loci were significant in two of these analyses (Supplementary Data 6): 
index variants rs1592757 / rs30266 (Refseq LOC105379109), rs28452470 / rs1443749 
(CADPS2), and rs2243638 / rs9574218 (RNF219-AS1). The CADPS2 locus has recently been 
identified in autism spectrum disorder as a novel locus shared with educational attainment93. 
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Meta-analysis with the 23andMe cohort also found genome-wide significant heterogeneity at the 
lead Chromosome 1 locus from the ADHD GWAS meta-analysis (rs12410155: I2 = 97.2, P = 
2.29 ´ 10-9; Supplementary Figures 20-21). This heterogeneity is consistent with the moderate 
sign concordance, effect size replication, and genetic correlation of the 23andMe cohort with the 
ADHD GWAS. Notably, the lead chromosome 1 locus in the ADHD GWAS overlaps a reported 
association with educational attainment78, suggesting this heterogeneity is consistent with the 
much weaker genetic correlation between the 23andMe results and published GWAS of 
education-related outcomes. No genome-wide significant heterogeneity was observed in the 
replication meta-analyses with deCODE or EAGLE/QIMR (Supplementary Figures 22-23, 
Supplementary Data 6).  
 
Discussion 
GWAS meta-analysis of ADHD revealed the first genome-wide significant risk loci, and 
indicates an important role for common variants in the polygenic architecture of ADHD. Several 
of the loci are located in or near genes that implicate neurodevelopmental processes that are 
likely to be relevant to ADHD, including FOXP2, SORCS3, and DUSP6. Future work may focus 
on refining the source of the strong association in each locus, especially the lead locus on 
chromosome 1 which is complicated by broad LD and substantial heterogeneity between ADHD 
the main meta-analysis and analysis of self-reported ADHD status in 23andMe. 
 
The 12 significant loci are compelling, but only capture a tiny fraction of common variant risk 
for ADHD. The odds ratios for the risk increasing allele at the index SNPs in the 12 significant 
loci are modest, ranging from 1.077 to 1.198 (Table 1).  This is within the range of effect sizes 
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for common genetic variants that has been observed for other highly polygenic psychiatric 
disorders e.g. schizophrenia33. A considerably larger proportion of the heritability of ADHD can 
be explained by all common variants (h2snp = 0.22, SE = 0.01).  This is consistent with previous 
estimates of h2snp for ADHD in smaller studies (h2snp: 0.1 - 0.28)23,24, and also comparable to SNP 
heritability estimates for schizophrenia (h2snp 0.23 - 0.26)23,24. As would be hypothesized for a 
psychiatric disorder, these effects are enriched in conserved regions and regions containing 
enhancers and promoters of expression in central nervous system tissues, consistent with 
previous observations in schizophrenia and bipolar disorder40. On the other hand, we do not 
observe substantial effects in most previously reported candidate genes for ADHD62. 
 
Along with polygenicity, selection and evolutionary pressures may be an important feature of the 
architecture of ADHD genetics. We observe that ADHD risk variants are strongly enriched in 
genomic regions conserved in mammals94, and constrained genes likely to be intolerant of loss-
of-function mutations91 are associated with ADHD. We also find that common variant risk for 
ADHD is genetically correlated with having children younger and having more children, in line 
with epidemiological findings of increased risky sexual behaviour95-97 and increased risk of 
ADHD for children born to young parents98-100. Given the phenotypic101,102 and genetic103 
correlation of ADHD with reduced educational attainment, positive selective pressure on the 
genetics of ADHD would be consistent with recent work suggesting that variants associated with 
educational attainment are under negative selection in Iceland104. Future studies of fecundity and 
the role of rare and de novo variants in ADHD may provide more insight on selective pressures 
in ADHD-associated loci.  
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The observed genetic correlations with educational outcomes and other phenotypes suggest a 
strong genetic component to the epidemiological correlates of ADHD. The significant positive 
genetic correlation of ADHD with major depressive disorder and depressive symptoms supports 
previous findings suggesting a positive genetic overlap between those phenotypes24,42, as well as 
the broader genetic overlap of psychiatric disorders23,24. Positive genetic correlations between 
ADHD and health risk behaviors such as smoking and obesity are consistent with the observed 
increase in those behaviors among individuals with ADHD105-108 and are indicative of a shared 
genetic basis for these traits. We also observe a positive genetic correlation of ADHD with 
insomnia, consistent with reports of sleep disturbances in ADHD109, but this relationship does 
not appear to generalize to other sleep-related phenotypes.  
 
These genetic correlations may not generalize to all settings. We observe much weaker genetic 
correlation of the 23andMe ADHD results with educational attainment, with only partial genetic 
correlation between 23andMe and the current ADHD GWAS, including significant heterogeneity 
in the lead chromosome 1 locus. The pattern of replication for the top loci in the deCODE study 
is stronger but still mixed. These differences may reflect dissimilarities in phenotyping (e.g. self-
report vs. medical records), exclusion of individuals with comorbid psychiatric disorders 
(deCODE), study population (e.g. higher average education and socio-economic status among 
23andMe research participants possibly under-representing the proportion of individuals with 
ADHD with poor educational outcomes in the general population), or other study factors that 
should be a focus of future work. 
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On the other hand, the replication results from EAGLE30/QIMR92 are much stronger and support 
the hypothesis that ADHD is the extreme expression of one or more heritable quantitative 
traits110. We observe strong concordance between the GWAS of ADHD and the previous 
GWASs of ADHD-related traits in the population, both in terms of genome-wide genetic 
correlation and concordance at individual loci. Polygenic risk for ADHD has previously been 
associated with inattentive and hyperactive/impulsive trait variation below clinical thresholds in 
the population29. Shared genetic risk with health risk behaviors may similarly be hypothesized to 
reflect an impaired ability to self-regulate and inhibit impulsive behavior111,112. The observed 
negative correlation between ADHD and anorexia nervosa may also be related to these 
behavioral factors.  
 
In summary, we report 12 independent genome-wide significant loci associated with ADHD in 
GWAS meta-analysis of 55,374 individuals from 12 study cohorts. The GWAS meta-analysis 
implicates FOXP2 and other biologically informative genes as well as constrained regions of the 
genome as important contributors to the etiology of ADHD. The results also highlight strong 
overlap with the genetics of ADHD-related traits and health risk behaviors in the population, 
encouraging a dimensional view of ADHD as the extreme end of a continuum of symptoms. 
 
URLs 
LD-Hub: http://ldsc.broadinstitute.org/ldhub/ 
LD score regression: https://github.com/bulik/ldsc 
Pre-computed European LD scores: https://data.broadinstitute.org/alkesgroup/LDSCORE/ 
PGC Ricopili GWA pipeline: https://github.com/Nealelab/ricopili  
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Credible set analysis: https://github.com/hailianghuang/FM-summary 
FUMA: http://fuma.ctglab.nl 
 
Supplementary Information is linked to the online version of the paper at 
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Figure legends 
 
Figure 1. Manhattan plot of the results from the GWAS meta-analysis of ADHD.  
The index variants in the 12 genome-wide significant loci are highlighted as a green diamond. 
Index variants located with a distance less than 400kb are considered as one locus. The y-axis 
represents –log(two-sided P-values) for association of variants with ADHD, from meta-analysis 
using an inverse-variance weighted fixed effects model, and a total sample size of 20,183 ADHD 
cases and 35,191 controls. The vertical red line represents the threshold for genome-wide 
significance. 
 
 
Figure 2. Odds Ratio by PRS for ADHD  
Odds Ratio (OR) by PRS within each decile estimated for n = 18,298 biological independent 
individuals in the PGC samples (red dots) and in n = 37,076 biological independent individuals 
in the iPSYCH sample (blue dots). PRSs in the iPSYCH sample were obtained by five leave-
one-out analyses, using 4 of 5 groups as training datasets for estimation of SNP weights, while 
estimating Polygenic Risk Scores (PRS) for the remaining target group. Odds ratios and 95% 
confidence limits (error bars) were estimated using logistic regression on the continuous scores. 
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Figure 3. Genetic correlations of ADHD with other phenotypes 
Significant genetic correlations between ADHD (results from Europena GWAS meta-analysis of 
19,099 cases, 34,194 controls) and other traits reveal overlap of genetic risk factors for ADHD 
across several groups of traits (grouping indicated by a horizontal line): educational, 
psychiatric/personality, weight (and possible weight related traits), smoking behaviour/smoking-
related cancer, reproductive traits and parental longevity (Sample size of the external GWASs 
are presented in Supplementary Table 5) . In total 219 traits were tested and only traits 
significant after Bonferroni correction are presented in the figure. Two significant educational 
phenotypes are omitted due to substantial overlap with years of schooling. Genetic correlation is 
presented as a dot and error bars indicate 95% confidence limits. 
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Table 1. Results for the genome-wide significant index variants in the 12 loci associated with ADHD identified in the GWAS meta-
analysis of 20,183 cases and 35,191 controls. Index variants are LD independent (r2 < 0.1), and are merged into one locus when located 
with a distance less than 400kb. The location (chromosome [Chr] and base position [BP]), alleles (A1 and A2), allele frequency (A1 
Freq), odds ratio (OR) of the effect with respect to A1, and association P-values from inverse-variance weighted fixed effects model, of 
the index variant are given, along with genes within 50kb of the credible set for the locus. 
 
           
Locus Chr BP Index Variant Genes A1 A2 A1 Freq OR P-value 
1 1 44184192 rs11420276   ST3GAL3, KDM4A, 
KDM4A-AS1, PTPRF, 
SLC6A9, ARTN, DPH2, 
ATP6V0B, B4GALT2, 
CCDC24, IPO13 
G GT 0.696 1.113 2.14 x 10-13  
2 1 96602440 rs1222063  Intergenic A G 0.328 1.101 3.07 x 10-8  
3 2 215181889 rs9677504  SPAG16 A G 0.109 1.124 1.39 x 10-8 
4 3 20669071 rs4858241  Intergenic T G 0.622 1.082 1.74 x 10-8 
5 4 31151456 rs28411770  PCDH7, LINC02497 T C 0.651 1.090 1.15 x 10-8  
6 5 87854395 rs4916723  LINC00461, MIR9-2, 
LINC02060, 
TMEM161B-AS1 
A C 0.573 0.926 1.58 x 10-8 
7 7 114086133 rs5886709  FOXP2, MIR3666 G GTC 0.463 1.079 1.66 x 10-8  
8 8 34352610 rs74760947  LINC01288 A G 0.957 0.835 1.35 x 10-8 
9 10 106747354 rs11591402  SORCS3 A T 0.224 0.911 1.34 x 10-8 
10 12 89760744 rs1427829  DUSP6, POC1B A G 0.434 1.083 1.82 x 10-9 
11 15 47754018 rs281324  SEMA6D T C 0.531 0.928 2.68 x 10-8 
12 16 72578131 rs212178  LINC01572 A G 0.883 0.891 7.68 x 10-9 
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Online Methods 
 
GWAS meta-analysis 
Quality control, imputation and primary association analyses were done using the bioinformatics 
pipeline Ricopili (available at https://github.com/Nealelab/ricopili), developed by the Psychiatric 
Genomics Consortium (PGC)33. In order to avoid potential study effects the 11 PGC samples and the 23 
genotyping batches within iPSYCH were each processed separately unless otherwise stated 
(Supplementary Information). 
Stringent quality control was applied to each cohort following standard procedures for GWAS, 
including filters for call rate, Hardy-Weinberg equilibrium, and heterozygosity rates (Supplementary 
Information). Each cohort was then phased and imputed using the 1000 Genomes Project phase 3 
(1KGP3)34,113 imputation reference panel using SHAPEIT114 and IMPUTE2115, respectively. For trio 
cohorts, pseudocontrols were defined from phased haplotypes prior to imputation. 
Cryptic relatedness and population structure were evaluated using a set of high quality markers pruned 
for linkage disequilibrium (LD). Genetic relatedness was estimated using PLINK v1.9116,117 to identify 
first and second-degree relatives (!" > 0.2) and one individual was excluded from each related pair. 
Genetic outliers were identified for exclusion based on principal component analyses using 
EIGENSOFT35,118. This was done separately for each of the PGC cohorts and on a merged set of 
genotypes for the iPSYCH cohort (Supplementary Information). Across studies, a total of 20,183 cases 
and 35,191 controls remained for analysis after QC. 
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Genome-wide association analyses for the 11 PGC samples and the 23 waves in iPSYCH were 
performed using logistic regression model with the imputed marker dosages in PLINK v1.9116,117. 
Principal components were included as covariates to control for population stratification35,118, along 
with relevant study-specific covariates where applicable (Supplementary Information, Supplementary 
Table 1). Subsequently the results were meta-analysed using an inverse-variance weighted fixed effects 
model, implemented in METAL (version 2011-03-25)36. Variants were filtered and included if 
imputation quality (INFO score) was > 0.8 and MAF > 0.01. Only markers supported by an effective 
sample size Neff = 4/(1/Ncases + 1/Ncontrols)119 greater than 70% were included. After filtering, the meta-
analysis included results for 8,047,421 markers.   
 
Conditional analysis 
Twelve independent genome-wide significant loci were identified by LD clumping and merging loci 
within 400 kb (Supplementary Information). In two of these loci a second index variant persisted after 
LD clumping. The two putative secondary signals were evaluated by considering analysis conditional 
on the lead index variant in each locus. In each cohort, logistic regression was performed with the 
imputed genotype dosage for the lead index variant included as a covariate. All covariates from the 
primary GWAS (e.g. principal components) were also included. The conditional association results 
were then combined in an inverse-variance weighted meta-analysis. 
 
Genetic correlations between ADHD samples 
Genetic correlation between the European-ancestry PGC and iPSYCH GWAS results was calculated 
using LD Score regression37. The regression was performed using pre-computed LD scores for 
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HapMap3 SNPs calculated based on 378 European-ancestry individuals from the 1000 Genomes Project 
(available on https://github.com/bulik/ldsc). Only results for markers with an imputation INFO score > 
0.90 were included in the analysis. In addition, a bivariate GREML analysis was conducted using 
GCTA120 in order to estimate the genetic correlation between PGC case/control and trio study designs. 
 
Polygenic Risk Scores for ADHD 
The iPSYCH sample were split into five groups, and subsequently five leave-one-out association 
analyses were conducted, using four out of five groups and the PGC samples as training datasets38. PRS 
were estimated for each target sample using variants passing a range of association P-value thresholds in 
the training samples. PRS were calculated by multiplying the natural log of the odds ratio of each 
variant by the allele-dosage (imputation probability) and whole-genome polygenic risk scores were 
obtained by summing values over variants for each individual.  
For each of the five groups of target samples, PRS were normalized and the significance of the case-
control score difference was tested by standard logistic regression including principal components. For 
each target group and for each P-value threshold the proportion of variance explained (i.e. Nagelkerke’s 
R2) was estimated by comparing the regression with PRS to a reduced model with covariates only. The 
OR for ADHD within each PRS decile group was estimated based on the normalized score across 
groups (using the P-value threshold with the highest Nagelkerke’s R2 within each target group) (Figure 
3). OR was also estimated using logistic regression on the continuous scores for each target group 
separately and an OR based on all samples using the normalized PRS score across all groups 
(Supplementary Figure 9). Additionally PRS were evaluated in the PGC samples using the iPSYCH 
sample as training sample, following the approach described above (Supplementary Information). 
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SNP heritability and intercept evaluation 
LD score regression37 was used to evaluated the relative contribution of polygenic effects and 
confounding factors, such as cryptic relatedness and population stratification, to deviation from the null 
in the genome-wide distribution of GWAS #$ statistics. Analysis was performed using pre-computed 
LD scores from European-ancestry samples in the 1000 Genomes Project (available on 
https://github.com/bulik/ldsc) and summary statistics for the European-ancestry ADHD GWAS to 
ensure matching of population LD structure. The influence of confounding factors was tested by 
comparing the estimated intercept of the LD score regression to one, it’s expected value under the null 
hypothesis of no confounding from e.g. population stratification. The ratio between this deviation and 
the deviation of the mean #$ from one (i.e. it’s expected value under the null hypothesis of no 
association) was used to estimate the proportion of inflation in #$ attributable to confounding as 
opposed to true polygenic effects (ratio = (intercept-1)/(mean #$-1)).  SNP heritability was estimated 
based on the slope of the LD score regression, with heritability on the liability scale calculated assuming 
a 5% population prevalence of ADHD39.  
 
Partitioning of the heritability 
SNP heritability was partitioned by functional category and tissue association using LD score 
regression40. Partitioning was performed for 53 overlapping functional categories, as well as 220 cell-
type-specific annotations grouped into 10 cell-type groups, as described in Finucane et al. 40. For both 
sets of annotations we used previously computed LD scores and allele frequencies from European 
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ancestry samples in the 1000 Genomes Project (available on 
https://data.broadinstitute.org/alkesgroup/LDSCORE/).  
Additionally we expanded the cell-type specific heritability analysis by including an annotation based 
on information about H3K4Me1 imputed gapped peaks excluding the broad MHC-region (chr6:25-
35MB), generated by the Roadmap Epigenomics Mapping Consortium121,122 (Supplementary 
Information). The analyses were restricted to the European GWAS meta-analysis results to ensure 
matching of population LD structure. Results for each functional category were evaluated based on 
marginal enrichment, defined as the proportion of SNP heritability explained by SNPs in the annotation 
divided by the proportion of genome-wide SNPs in the annotation40. For each cell-type group and each 
H3K4Me1 cell-type annotations, the contribution to SNP heritability was tested conditional on the 
baseline model containing the 53 functional categories.   
 
Genetic correlations of ADHD with other traits 
The genetic correlations of ADHD with other phenotypes were evaluated using LD Score regression42. 
For a given pair of traits, LD score regession estimates the expected population correlation between the 
best possible linear SNP-based predictor for each trait, restricting to common SNPs. Such correlation of 
genetic risk may reflect a combination of colocalization, pleiotropy, shared biological mechanisms, and 
causal relationships between traits.   Correlations were tested for 211 phenotypes with publically 
available GWAS summary statistics using LD Hub41 (Supplementary Information). Additonally, we 
analysed on our local computer cluster, the genetic correlation of ADHD with eight phenotypes: human 
intelligence103, four phenotypes related to education and cognition analyzed in samples from the 
UK_Biobank49 (college/university degree, verbal–numerical reasoning, memory and reaction time), 
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insomnia60, anorexia nervosa44, and major depressive disorder43. The genetic correlation with major 
depressive disorder was tested using GWAS results from an updated analysis of 130,664 cases with 
major depressive disorder and 330,470 controls from the Psychiatric Genomics Consortium. As in the 
previous LD score regression analyses, this estimation was based on summary statistics from the 
European GWAS meta-analysis, and significant correlations reported are for traits analysed using 
individuals with European ancestry.  
 
Credible set analysis 
We defined a credible set of variants in each locus using the method described by Maller et al.123 
(Supplementary Information), implemented by a freely available R script 
(https://github.com/hailianghuang/FM-summary). Under the assumption that (a) there is one causal 
variant in each locus, and (b) the causal variant is observed in the genotype data, the credible set can be 
considered to have a 99% probability of containing the causal variant. For each the 12 genome-wide 
significant loci, variants within 1MB and in LD with correlation  r2 > 0.4  to the index variant were 
considered for inclusion in the credible set analysis. The credible set analysis was done using the 
European GWAS meta-analysis to ensure consistent LD structure in the analyzed cohorts.  
 
Biological annotation of variants in credible set 
The variants in the credible set for each locus, were annotated based on external reference data in order 
to evaluate potential functional consequences. In particular, we identify: (a) Gene and regulatory 
consequences annotated by Variant Effect Predictor (VEP) using Ensembl with genome build 
GRCh37124. We exclude upstream and downstream consequences, and consequences for transcripts that 
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lack a HGNC gene symbol (e.g. vega genes). (b) Variants within 2kb upstream of the transcription start 
site (TSS) of at least one gene isoform based on Gencode v19125. (c) Variants annotated as interacting 
with a given gene in Hi-C data from samples of developing human cerebral cortex during neurogenesis 
and migration126. Annotations are considered for both the germinal zone (GZ), primarily consisting of 
actively dividing neural progenitors, and the cortical and subcortical plate (CP), primarily consisting of 
post-mitotic neurons. (d) Variants identified as eQTLs based on gene expression in GTEx127 or BIOS79. 
Expression quantitative trait loci were annotated using FUMA (http://fuma.ctglab.nl/). We restricted to 
eQTL associations with false discovery fate (FDR) < 1e-3 within each dataset. (e) Chromatin states of 
each variant based on the 15-state chromHMM analysis of epigenomics data from Roadmap128. The 15 
states summarize to annotations of active chromatin marks (i.e. Active TSS, Flanking Active TSS, 
Flanking Transcription, Strong Transcription, Weak Transcription, Genic Enhancer, Enhancer, or Zinc 
Finger [ZNF] gene), repressed chromatin marks (Heterochromatin, Bivalent TSS, Flanking Bivalent 
TSS, Bivalent Enhancer, Repressed Polycomb, or Weak Repressed Polycomb), or quiescent. The most 
common chromatin state across 127 tissue/cell types was annotated using FUMA 
(http://fuma.ctglab.nl/). We also evalauted the annotated chromatin state from fetal brain.   
 
Gene-set analyses 
Gene-based association with ADHD was estimated with MAGMA 1.0588 using the summary statistics 
from the European GWAS meta-analysis (Ncases = 19,099, Ncontrols = 34,194; Supplementary 
Information, Supplementary Information Table 1).  Association was tested using the SNP-wise mean 
model, in which the sum of -log(SNP P-value) for SNPs located within the transcribed region (defined 
using NCBI 37.3 gene definitions) was used as the test statistic. MAGMA accounts for gene-size, 
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number of SNPs in a gene and LD between markers when estimating gene-based P-values. LD 
correction was based on estimates from the 1000 genome phase 3 European ancestry samples34.  
The generated gene-based P-values were used to analyze sets of genes in order to test for enrichment of 
association signals in genes belonging to specific biological pathways or processes. In the analysis only 
genes on autosomes, and genes located outside the broad MHC region (hg19:chr6:25-35M) were 
included. We used the gene names and locations and the European genotype reference panel provided 
with MAGMA. For gene sets we used sets with 10-1000 genes from the Gene Ontology sets86 currated 
from  MsigDB 6.087.  
Targeted FOXP2 downstream target gene sets were analysed for association with ADHD. Three sets 
were examined: 1) Putative target genes of Foxp2 that were enriched in wild type compared to control 
Foxp2 knockout mouse brains in ChIP-chip experiments (219 genes), 2) Genes showing differential 
expression in wild type compared to Foxp2 knockout mouse brains (243 genes), and 3) FOXP2 target 
genes that were enriched in either or both basal ganglia (BG) and inferior frontal cortex (IFC) from 
human fetal brain samples in ChIP-chip experiments (258 genes). Curated short lists of high-confidence 
genes were obtained from Vernes et al.89 and Spiteri et al90. 
A set of evolutionarily highly constrained genes were also analysed. The set of highly constrained genes 
was defined using a posterior probability of being loss-of-function intolerant (pLI) based on the 
observed and expected counts of protein-truncating variants (PTV) within each gene in a large study of 
over 60,000 exomes from the Exome Aggregation Consortium (ExAC)91. Genes with pLI ≥0.9 were 
selected as the set of highly constrained genes (2932 genes).  
 
Replication of GWAS loci 
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To replicate the results of the ADHD GWAS meta-analysis we compared the results to analyses of 
cohorts from deCODE and 23andMe, and a meta-analysis of two independent studies conducted by 
EAGLE and QIMR (referred to as EAGLE/QIMR). We evaluated evidence for replication based on: (a) 
sign tests of concordance between the ADHD GWAS meta-analysis and each replication cohort; (b) 
comparison of bias-corrected effect sizes between the ADHD GWAS and the deCODE and 23andMe 
replication cohorts; (c) genetic correlation between the ADHD GWAS and the 23andMe and 
EAGLE/QIMR replication cohorts; (d) meta-analysis of the ADHD GWAS meta-analysis results with 
the results from each replication cohort; and (e) tests of heterogeneity between the ADHD GWAS and 
each replication cohorts. 
For the sign test, we first identified the overlapping SNPs present in the ADHD GWAS and each of the 
three replication analyses (i.e. deCODE, 23andMe, and EAGLE/QIMR). For each replication cohort 
intersecting SNPs were then clumped for LD (r2 > 0.05 within 1 Mb) for all variants with P < 1 ´ 10-4 in 
the ADHD GWAS (or P < 1 ´ 10-5 for the deCODE replication) using 1000 Genomes Phase 3 data on 
European ancestry populations. After clumping, sign tests were performed to test the proportion of loci 
with a concordant direction of effect in the replication cohort (p) using a one sample test of the 
proportion with Yates’ continuity correction129 against a null hypothesis of p = 0.50 (i.e. the signs are 
concordant between the two analyses by chance) in R130. This test was evaluated separately for 
concordance in deCODE, 23andMe, and EAGLE/QIMR for loci passing P-value thresholds of P < 5 ´ 
10-8 (i.e. genome-wide significant loci), P < 1 ´ 10-7, P < 1 ´ 10-6, P < 1 ´ 10-5, and P < 1 ´ 10-4 in the 
ADHD GWAS meta-analysis (Supplementary Information).  
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In addition to testing concordance for the direction of effect, we also evaluate replication for the 
magnitude of the effect sizes. Specifically, for each of deCODE and 23andMe we regressed the effect 
size in the replication cohort (i.e. the log odds ratio) on the estimated effect size from the ADHD 
GWAS after adjustment for winner’s curse for loci with P < 1e-6. Winner’s curse correction is 
perfomed by computing posterior mean estimates of marginal SNP effects %& after fitting a spike-and-
alab distribution  
%&~ ( 0*(0, -$)with	probability	!otherwise  
by maximum likelihood as described by Okbay et al.78 (Supplementary Information). For the regression 
of effect sizes we oriented all variants in the direction of the risk increasing allele estimated from the 
ADHD GWAS, constrained the intercept to zero, and weighted the variants proportional to the inverse 
of their squared standard error from the ADHD GWAS. A regression slope of one indicates “ideal” 
replication of all loci in the regression, whereas a slope of zero indicates no replication. 
Genetic correlation of the ADHD GWAS with the 23andMe and EAGLE/QIMR results was computed 
using LD score regression37 with pre-computed European ancestry LD scores following the same 
procedure as described above for other genetic correlation analyses. Genetic correlation could not be 
computed for deCODE since results were only available for top loci from the ADHD GWAS. To further 
explore the moderate genetic correlation between the 23andMe results and the ADHD GWAS we also 
evaluated the genetic correlation between 23andMe and traits from LD Hub 
(http://ldsc.broadinstitute.org/ldhub/)42. To evaluate the magnitude of the observed differences in rg we 
consider both the absolute difference (i.e. =>?,@ABA − >?,$DEFGHI =) and the test of an approximate Z score 
for this difference (Supplementary Information): 
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J = >?,@ABA − >?,$DEFGHILMN@ABA$ + MN$DEFGHI$
 
We do not expect this to be an ideal formal test for the difference between two genetic correlations, and 
therefore emphasize caution in interpreting the precise results. Nevertheless, it does offer a useful 
benchmark for evaluating the magnitude of the difference between the rg estimates in the context of the 
uncertainty in those values. 
Finally, we meta-analyzed the ADHD GWAS with the results from each replication cohort. For 
deCODE and 23andMe inverse variance-weighted meta-analyses were performed. For meta-analysis 
with the EAGLE/QIMR GWAS of ADHD-related behaviors in childhood population samples we used a 
modified sample size-based weighting method. Modified sample size-based weights were derived to 
accounts for the respective heritabilities, genetic correlation, and measurement scale of the GWASs 
(Supplementary Information). To summarize, given z-scores Z1j and Z2j resulting from GWAS of SNP j 
in a dichotomous phenotype (e.g. ADHD) with sample size NI and a continuous phenotype (e.g. ADHD-
related traits) with sample size N2, respectively, we calculate 
J&,PIQE =
R*ST&JT& + R*S$&JU$&
R*ST& +*S$&
 
where 
JU$& = VWXYZ>?[	´	 J$&
R1+ Z1 − >?$[*$&ℎ$$ &^ _⁄
 
*ST& = *T& a(1 − a)	b(c
dT[f])$
[f(1 − f)]$  
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*S$& = *$& >?
$ℎ$$ ℎT$⁄
1 + (1 − >?$) *$&ℎ$$ &^ _⁄  
 
The adjusted sample sizes *Th and *$h  reflect differences in power between the studies due to 
measurement scale and relative heritability that is not captured by sample size. The calculation of J$h 
reduces the contribution of the continuous phenotype’s GWAS to the meta-analysis based on imperfect 
genetic correlation with the dichotomous phenotype of interest (i.e. ADHD). The adjustments are 
computed based on the sample prevalence (P) and population prevalence (K) of the dichotomous 
phenotype, the estimated liability scale SNP heritability of the two phenotypes (ℎT$ and ℎ$$), and the 
genetic correlation (rg) between the two phenotypes, as well as the average SNP LD score (lj) and the 
number of SNPs (M). Heritability and genetic correlation values to compute these weights are computed 
using LD score regression. This meta-analysis weighting scheme is consistent with weights alternatively 
derived based on modelling the joint distribution of marginal GWAS beta across traits131. 
To test heterogeneity with each replication cohort, we considered Cochran’s Q test of heterogeneity in 
the meta-analyses. Specifically, we evaluated the one degree of freedom test for heterogeneity between 
the ADHD GWAS meta-analysis and the replication cohort.  
 
Data Avalibility Statement 
The PGC’s policy is to make genome-wide summary results public. Summary statistics with the results 
from the ADHD GWAs meta-analysis of iPSYCH and the PGC samples are available on the PGC 
website (https://www.med.unc.edu/pgc/results-and-downloads). GWA summary statistics with results 
from the GWAS of ADHD symptom scores analyzed in the EAGLE sample can be accessed at the PGC 
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website (see link above). Summary statistics for the 23andMe dataset can be obtained by qualified 
researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants.  
  
Availability of genotype data and summary statistics 
For access to genotypes from the PGC cohorts and the iPSYCH sample interested researchers should 
contact the lead PIs (iPSYCH: lead PI Anders D. Børglum; PGC: Benjamin Neale and Stephen 
Faraone). Summary statitistics can be downloaded from: https://www.med.unc.edu/pgc/results-and-
downloads 
http://ipsych.au.dk/downloads/   
http://www.wikigenes.org/e/art/e/348.html 
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